Our study implicates a novel toxic ERVK protein in MLKL-driven pathology and myelin damage in ALS neurodegeneration and broadens the outlook on potential therapeutic strategies for ALS. This evidence concerns the gene MLKL and amyotrophic lateral sclerosis.